EN Mobile Logo

Search form



Slower Eating Increases Satiety, Reduces Hunger in Type 2 Diabetes

Faulty brain satiety centers and impaired gut hormone function are risk factors for weight gain in T2 diabetes. A simple antidote? Slow down.


A new study evaluated the comparative effectiveness and safety of monotherapy and selected metformin-based combinations for type 2 diabetes.

Clinical trials have shown that GLP-1 RAs reduce HbA1c and weight in type 2 diabetes, but are these outcomes confounded by concomitant medications?

A meta-analysis examined the effect of treatment with a GLP-1 receptor agonist on cardiovascular event risk in type 2 diabetes patients.

Unlike typical Western patients, type 2 diabetes patients in Asia tend to have lower BMIs. Does this mean responses to GLP-1 RAs differ as well?

Does a GLP-1 receptor agonist offer the same weight-loss benefits to different racial subgroups?

Which GLP-1 receptor agonist induced weight loss in type 2 diabetes patients?


Take a short break from the clinic and try 2 quick questions about the injectable gut hormone analogs.


Subscribe to Incretins on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.